24/7 Market News Snapshot 01 May, 2025 – Olo Inc. (NYSE:OLO)

May 1, 2025

DENVER, Colo., 01 May, 2025 (www.247marketnews.com) – (NYSE:OLO) are discussed in this article.
Olo Inc. (OLO) commenced trading today at $6.90, reflecting a notable bullish trend with a price surge of approximately 15.24%. Currently at $7.145, the stock is experiencing robust buying interest, as indicated by a trading volume of 4.10 million shares. This increase in volume highlights the growing investor confidence and engagement surrounding Olo’s growth trajectory. Technical indicators suggest potential for further upward movement, contingent on sustaining levels above critical resistance points. Investors are advised to closely monitor subsequent price actions and trading volumes to gauge ongoing sentiment in the marketplace.

In a parallel development, iRhythm Technologies, Inc., renowned for its advancements in digital healthcare solutions, reported impressive financial outcomes for the first quarter of 2025. The company achieved revenue of $158.7 million, signifying a significant 20.3% year-over-year increase, driven by heightened demand for its Zio services within evolving, value-based care paradigms. The gross margin improved markedly to 68.8%, reflecting an ascent of 250 basis points from the previous year’s figures, underscoring iRhythm’s commitment to operational efficiency while scaling service delivery amid escalating market demands.

Quentin Blackford, President and CEO of iRhythm, emphasized the importance of these results, stating, “Our first quarter outcomes illustrate our relentless momentum in providing value through our advanced health solutions.” The recent launches of the Zio monitor in international markets, particularly in Japan, have further solidified iRhythm’s vision to enhance accessibility to innovative solutions globally. Recent major studies presented at ACC.25 reaffirm the efficacy of their monitoring products, emphasizing the inadequacies of short-term Holter monitoring in detecting vital arrhythmias.

As of March 31, 2025, iRhythm maintained a robust financial position with cash, cash equivalents, and marketable securities totaling $520.6 million, positioning the company to capitalize on growth initiatives. With 2025 revenue projections ranging from $690 million to $700 million and an adjusted EBITDA margin anticipated between 7.5% and 8.5%, iRhythm continues to play a critical role in revolutionizing healthcare delivery through innovative technology solutions.

Related news for (OLO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.